FOXP2 and diffuse large B-cell lymphoma: In multivariate analyses (Table 2), DLBCL patients with ≥ 20% FOXP2 expression exhibited significantly inferior outcome independent of either a high IPI score (OS: P = 0.0119; PFS: P = 0.0451) or non-GCB DLBCL subtype according to Hans (OS: P = 0.0047; PFS: P = 0.0186), Choi (OS: P = 0.0059; PFS: P = 0.0258) and Visco-Young (OS: P = 0.0098; PFS: P = 0.0367) algorithms.